Menstrual cramps are the one women's-health use with even a modest real-world human signal, and it comes tangled up: every human study mixed the terpene in with CBD and THC, so no one can say the terpene did the work.
What patients are managing
Menstrual health is not a qualifying condition in Pennsylvania's medical program, though patients sometimes qualify through a related condition. Period pain and PMS are prostaglandin-driven, and cannabis products are increasingly marketed for them. There is a little human evidence here, more than for perimenopause, and it comes with a specific catch worth understanding before you buy.
What the research supports: cannabinoids
The human evidence is uncontrolled and whole-product. A high-CBD vaginal suppository study reported reduced menstrual pain and lower painkiller use, and a real-world report of a whole-plant suppository, CBD plus a little THC plus added beta-caryophyllene and humulene, found large self-reported drops in pain across hundreds of uses. Both are uncontrolled, unblinded, and self-reported, which is why this rates as promising but low-quality. There is a mechanism catch too: cannabis has not been shown to reduce prostaglandins, so how it eases cramps is unclear.
What the research supports: terpenes
Beta-caryophyllene is the plausible terpene here, a CB2 agonist that reduced pain in a rodent study and that shows up in human menstrual products. But in every human result it is co-formulated with CBD and THC, so its own contribution cannot be separated out. Humulene has only preclinical anti-inflammatory data, and myrcene, linalool, and limonene have no menstrual-specific human evidence. No study isolates a single cannabis terpene against a menstrual outcome in a person.
What the research does not support
No study shows a terpene on its own relieving menstrual pain, because every human result mixed the terpene with cannabinoids. The whole-product evidence is uncontrolled, and cannabis has not been shown to act on the prostaglandins that drive cramps. A Fit score that credited the terpene for the relief would be claiming something the studies were not built to show. Beta-caryophyllene is the best candidate, and even it has never been tested alone.
How Terpenology scores this
Terpenology can show a modest, low-confidence menstrual score framed as pain and inflammation symptom support, and it does not claim the terpene is doing the work. Beta-caryophyllene earns a modest signal on mechanism, with the note that the human evidence comes from whole-product CBD studies rather than isolated terpenes, and with the caveat that cannabis is not shown to reduce prostaglandins.
Terpenes worth reading about
Terpenology is educational, not medical advice. Terpene effects are tendencies commonly reported by patients and early research, never guaranteed outcomes. Nothing here is a substitute for the care of your certifying physician, your pharmacist, or the specialist treating your condition.